FDAsafety guidance66% confidence
Convenience Kit Correction: Medline Issues Correction for Kits Containing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Medline is correcting affected convenience kits by removing recalled Bupivacaine Hydrochloride in Dextrose Injection components.
Supporting Context
- Therapeutic area
- Infectious Disease · HIV
- Sub-indication
- General
Related signal: FDA Accepts NDA for IDVYNSO Containing Doravirine and Islatravir